Abbott Laboratories delivered a second quarter in which the headline 13.0% reported sales growth and 4.8% comparable growth obscured the real story: a $20 billion acquisition of Exact Sciences that closed on March 23, 2026 has redrawn the company's diagnostic footprint, lifted reported goodwill and intangible assets by more than $23 billion combined, and pushed long-term debt from $9.9 billion at year-end 2025 to $29.6 billion by mid-year 2026. Underneath that transaction, the underlying franchise showed clear bifurcation, with Medical Devices continuing to compound at a high-single-digit comparable rate led by electrophysiology and diabetes care, Established Pharmaceuticals growing 8.7% on a comparable basis in major emerging markets, Nutrition turning in another soft quarter, and Diagnostics growth ex-Cancer running below three percent. Reported GAAP earnings per share collapsed to $0.53 from $1.01 a year ago, but only because the quarter absorbed $1.36 billion of specified items including a $385 million legal reserve, acquisition-related charges, and intangible amortization; adjusted diluted EPS of $1.31 still grew 4.0% year-over-year. Management raised the full-year 2026 adjusted EPS guidance range to $5.45 to $5.60 from the prior $5.38 to $5.58, reaffirmed comparable sales growth guidance of 6.5% to 7.5%, and declared the 410th consecutive quarterly dividend at $0.63 per share, maintaining the company's place in the S&P 500 Dividend Aristocrats Index with 54 consecutive years of increases. The market is now valuing Abbott at roughly $191 billion of equity against a balance sheet carrying approximately $27.5 billion of net debt post-Exact Sciences, and the next six months test whether the Cologuard franchise and Abbott's structural-heart pipeline can carry the multiple while free cash flow absorbs higher interest expense from the new capital structure.